NLRP3 and endothelial dysfunction: Most randomized trials, including CANTOS, COLCOT, and LoDoCo2, initiated therapy days to weeks after the index event, well beyond the 3-to-7-day peak of inflammatory activity when NLRP3 activation, NETosis, endothelial dysfunction, and defective resolution are most modifiable [3,4,119].